PMID- 23522918
OWN - NLM
STAT- MEDLINE
DCOM- 20140110
LR  - 20130603
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 2
DP  - 2013 May
TI  - The effects of diabetes mellitus and diabetic nephropathy on bone and mineral 
      metabolism in T2DM patients.
PG  - 272-6
LID - S0168-8227(13)00085-5 [pii]
LID - 10.1016/j.diabres.2013.03.007 [doi]
AB  - AIM: To assess the effects of both diabetes mellitus and diabetic nephropathy on 
      bone mineral metabolism in patients with type 2 diabetes mellitus (T2DM). 
      METHODS: Serum osteocalcin (BGP), serum alkaline phosphatase (ALP), bone-specific 
      alkaline phosphatase (BAP), 24-h urinary hydroxyproline (HOP), blood and urine 
      calcium (Ca), phosphate (P) levels and bone mineral density (BMD) were assessed 
      and compared in 30 patients with T2DM (group D), 25 T2DM patients with 
      nephropathy (group DN) and 27 nondiabetic control subjects (group C). RESULTS: 
      Compared with the nondiabetic controls, patients in both groups D and DN had 
      decreased serum osteocalcin (BGP) and bone mineral density (BMD) while serum 
      alkaline phosphatase (ALP) and urinary hydroxyproline (HOP) were increased. 
      Decrease in BGP was not correlated with ALP (r = -0.1, P<0.37). Within both 
      diabetes groups (group D and group DN), no significant change in BAP is observed, 
      however group DN showed higher level of BGP, higher level of HOP and lower BMD 
      than group D. Urine calcium was increased in both group D and DN with group D 
      having higher levels than group DN. In DN patients had increased circulating 
      phosphate and decreased urinary excretion of phosphate, while decreased 
      circulating phosphate and increased urinary excretion phosphate are seen in group 
      D patients. CONCLUSION: Patients with T2DM show an imbalance of bone mineral 
      metabolism, and co-existence of nephropathy tends to aggravate this. Serum 
      osteocalcin and 24-h hydroxyproline may be considered useful biochemical markers 
      for monitoring possible bone mineral metabolism disorder in T2DM patients.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Chen, Hui
AU  - Chen H
AD  - Department of Endocrinology, The Second Hospital of Lanzhou University, Lanzhou 
      730030, PR China. 13909313366@163.com
FAU - Li, Xiaoxu
AU  - Li X
FAU - Yue, Ruihong
AU  - Yue R
FAU - Ren, Xuan
AU  - Ren X
FAU - Zhang, Xiude
AU  - Zhang X
FAU - Ni, Anming
AU  - Ni A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130321
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Phosphates)
RN  - 104982-03-8 (Osteocalcin)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - RMB44WO89X (Hydroxyproline)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alkaline Phosphatase/blood
MH  - Bone Density/physiology
MH  - Calcium/blood/urine
MH  - Diabetes Mellitus, Type 2/blood/*metabolism/physiopathology/urine
MH  - Diabetic Nephropathies/blood/*metabolism/physiopathology/urine
MH  - Female
MH  - Humans
MH  - Hydroxyproline/blood/urine
MH  - Male
MH  - Middle Aged
MH  - Osteocalcin/*blood
MH  - Phosphates/blood/urine
EDAT- 2013/03/26 06:00
MHDA- 2014/01/11 06:00
CRDT- 2013/03/26 06:00
PHST- 2012/10/01 00:00 [received]
PHST- 2013/02/21 00:00 [revised]
PHST- 2013/03/01 00:00 [accepted]
PHST- 2013/03/26 06:00 [entrez]
PHST- 2013/03/26 06:00 [pubmed]
PHST- 2014/01/11 06:00 [medline]
AID - S0168-8227(13)00085-5 [pii]
AID - 10.1016/j.diabres.2013.03.007 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 May;100(2):272-6. doi: 
      10.1016/j.diabres.2013.03.007. Epub 2013 Mar 21.